Update Mammakarzinom 2021 Teil 5 – fortgeschrittenes Mammakarzinom Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer

Despite the COVID 19 pandemic and mostly virtual congresses, innovation in the treatment of breast cancer patients continues at an unabated pace. This review summarises the current developments. Initial overall survival data for CDK4/6 inhibitor treatment in combination with an aromatase inhibitor as the first advanced line of therapy in treatment-naive postmenopausal patients have been published. Similarly, a trial comparing trastuzumab-deruxtecan versus trastuzumabemtansine revealed a clear benefit regarding progression-free survival. Understanding of biomarkers making checkpoint inhibitor therapy particularly effective is increasing, and new compounds such as oral selective estrogen receptor destabilisers (SERDs) are entering clinical development and completing the first phase III trials. Su pp le m en ta ry M at er ia l – de ut sc hs pr ac hi ge Zu sa tz in fo rm at io n! Zi ti er ba r is t au ss ch lie ß lic h de r en gl is ch sp ra ch ig e A rt ik el . GebFra Science | Übersicht

[1]  M. Lux,et al.  Correction: Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer , 2022, Geburtshilfe und Frauenheilkunde.

[2]  P. Fasching,et al.  Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  J. O’Shaughnessy,et al.  LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer , 2021, Annals of Oncology.

[4]  G. Curigliano,et al.  LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study , 2021, Annals of Oncology.

[5]  G. Hortobagyi,et al.  LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB) , 2021, Annals of Oncology.

[6]  S. Loi,et al.  LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC , 2021, Annals of Oncology.

[7]  P. Fasching,et al.  LBA14 Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study , 2021, Annals of Oncology.

[8]  H. Linden,et al.  264P AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) , 2021, Annals of Oncology.

[9]  D. Juric,et al.  A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer , 2021, Clinical Cancer Research.

[10]  Siew K. Yeap,et al.  GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer. , 2021, Journal of medicinal chemistry.

[11]  J. Flanagan,et al.  Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer , 2021, Experimental and Molecular Therapeutics.

[12]  Joon Sang Lee,et al.  Abstract 739: Preclinical and clinical activity of SAR439859, Amcenestrant, a next generation SERD , 2021, Endocrinology.

[13]  Brian E. Mattioni,et al.  Abstract 1236: Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD) , 2021, Experimental and Molecular Therapeutics.

[14]  Y. Wang,et al.  Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  M. Goetz,et al.  Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups , 2021, NPJ breast cancer.

[16]  Ying Lin,et al.  Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial. , 2021 .

[17]  Leonard D. Goldstein,et al.  The tumor microenvironment (TME) and atezolizumab + nab-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130. , 2021 .

[18]  S. Loi,et al.  Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3. , 2021 .

[19]  Sung-Bae Kim,et al.  A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study. , 2021 .

[20]  P. Neven,et al.  Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2– advanced breast cancer: Phase 1 results. , 2021 .

[21]  H. Linden,et al.  AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). , 2021 .

[22]  P. Fasching,et al.  Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase 3 randomized MONALEESA-3 trial: updated overall survival. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  M. Lux,et al.  Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients , 2021, Geburtshilfe und Frauenheilkunde.

[24]  P. Fasching,et al.  Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer , 2021, Clinical Cancer Research.

[25]  S. Loi,et al.  Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer , 2021 .

[26]  M. Korpal,et al.  Abstract PD8-06: Phase I/II trial of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer , 2021 .

[27]  D. Juric,et al.  Abstract PS11-26: A phase 1 study of D-0502, an orally bioavailable SERD, for advanced or metastatic HR-positive and HER2-negative breast cancer , 2021 .

[28]  P. Neven,et al.  Abstract PS12-04: Rintodestrant (G1T48), an oral selective estrogen receptor degrader in ER+/HER2- locally advanced or metastatic breast cancer: Updated phase 1 results and dose selection , 2021 .

[29]  L. Chow,et al.  Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib , 2021 .

[30]  M. Beeram,et al.  Abstract OT-09-03: EMBER: A phase 1a/b trial of LY3484356, a novel, oral selective estrogen-receptor degrader (SERD), in advanced ER+ breast cancer and endometroid endometrial cancer , 2021 .

[31]  A. Bardia,et al.  Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Ahn， Jin Hee,et al.  Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial , 2020, The Lancet.

[33]  M. Lux,et al.  Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab , 2020, Cancers.

[34]  F. Doñate,et al.  Abstract 4373: Discovery of ZN-c5, a novel potent and oral selective estrogen receptor degrader , 2020 .

[35]  James S. Scott,et al.  Abstract 5674: Discovery of AZD9833, an oral small molecule selective degrader of the estrogen receptor (SERD) , 2020 .

[36]  S. Loi,et al.  Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer , 2020, Journal of the National Cancer Institute.

[37]  I. Bièche,et al.  Prognostic impact of ESR1 mutations in ER+ HER2- MBC patients prior treated with first line AI and palbociclib: An exploratory analysis of the PADA-1 trial. , 2020 .

[38]  P. Neven,et al.  Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials. , 2020 .

[39]  P. Fasching,et al.  Abstract PD5-08: Tumor immune-cell activity assessed by RNAseq is an independent predictor of therapy response and prognosis after neoadjuvant chemotherapy in HER2 negative breast cancer patients - An analysis of the GeparSepto trial , 2020 .

[40]  W. Gradishar.  The 2019 San Antonio Breast Cancer Symposium , 2020 .

[41]  P. Fasching,et al.  Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. , 2019, The New England journal of medicine.

[42]  R. Greil,et al.  Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. , 2019, The New England journal of medicine.

[43]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. , 2019, The New England journal of medicine.

[44]  E. Winer,et al.  Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[45]  P. Neven,et al.  The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 , 2019, JAMA oncology.

[46]  L. Chow,et al.  Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. , 2019, The New England journal of medicine.

[47]  A. Guerrero-Zotano,et al.  Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study , 2019, Breast Cancer Research and Treatment.

[48]  H. Rugo,et al.  Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer , 2019, The New England journal of medicine.

[49]  A. Daemen,et al.  Abstract P5-04-07: GDC-9545: A novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes , 2019, Poster Session Abstracts.

[50]  S. Loi,et al.  Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer , 2018, The New England journal of medicine.

[51]  L. Chow,et al.  Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. , 2018, The Lancet. Oncology.

[52]  P. Fasching,et al.  Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  M. Beckmann,et al.  Abstract P5-21-09: Overall survival of metastatic breast cancer patients – data from the PRAEGNANT breast cancer registry , 2018 .

[54]  M. Lux,et al.  TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients – First Results on the Influence of Tumor-Infiltrating Lymphocytes , 2018, Geburtshilfe und Frauenheilkunde.

[55]  P. Fasching,et al.  Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. , 2018, The Lancet. Oncology.

[56]  M. Goetz,et al.  MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  P. Neven,et al.  MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  I. Mellman,et al.  Elements of cancer immunity and the cancer–immune set point , 2017, Nature.

[59]  K. Gelmon,et al.  Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.

[60]  Massimo Cristofanilli,et al.  Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. , 2015, The New England journal of medicine.

[61]  Gordon B Mills,et al.  Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer , 2014, Clinical Cancer Research.

[62]  M. Beckmann,et al.  Prognostic value of HER2 on breast cancer survival. , 2013 .

[63]  J. Robertson.  Fulvestrant (Faslodex) -- how to make a good drug better. , 2007, The oncologist.

[64]  V. Jordan,et al.  “Studies on the estrogen receptor in breast cancer” — 20 years as a target for the treatment and prevention of cancer , 2004, Breast Cancer Research and Treatment.

[65]  S. Kuentzel,et al.  CC-1065 (NSC-298223), a new antitumor antibiotic. Production, in vitro biological activity, microbiological assays and taxonomy of the producing microorganism. , 1978, The Journal of antibiotics.